ARO-MUC5AC is an inhalation solution being studied for its effects on people with muco-obstructive lung disease. This medication is designed to help manage symptoms by targeting and reducing mucus production in the lungs, which can improve breathing and overall lung function. The trial aims to evaluate how safe and tolerable this treatment is for both healthy individuals and patients with lung conditions.

Asthma – Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to difficulty in breathing. It often presents with symptoms such as wheezing, coughing, shortness of breath, and chest tightness. These symptoms can vary in intensity and may be triggered by allergens, exercise, cold air, or stress. Asthma can progress with episodes known as asthma attacks, where symptoms become more severe. The condition can fluctuate over time, with periods of exacerbation and remission. Management typically involves avoiding triggers and monitoring symptoms to prevent attacks.

Chronic Obstructive Pulmonary Disease (COPD) – Chronic Obstructive Pulmonary Disease is a progressive lung disease that causes obstructed airflow from the lungs. It is primarily caused by long-term exposure to irritating gases or particulate matter, most often from cigarette smoke. Symptoms include breathing difficulty, cough, mucus production, and wheezing. COPD develops slowly over years and can lead to increasing breathlessness. The disease is characterized by episodes of exacerbation, where symptoms worsen and may require additional care. It is important to manage environmental factors and monitor lung function to slow progression.